

Pharmacy and Therapeutics Committee Approvals, June 2007

P&T Date: June 5, 2007

AGENDA ITEM	P&T COMMITTEE DECISION	COMMENTS
<ul style="list-style-type: none"> • OPHTHALMIC ANTIHISTAMINES 	<p style="text-align: center;">KETOTIFEN (ZADITOR®) ADDED TO FORMULARY.</p>	<ul style="list-style-type: none"> • Indication: Temporary prevention of itching of the eye due to allergic conjunctivitis. Safety and efficacy in children < 3 years of age not established • Mechanism of Action: Histamine₁ receptor antagonism and mast cell stabilization. • Adverse effects: Most common: headache (up to 25%), ocular burning/stinging (≤ 10%) • Precautions: Pregnancy category C
<ul style="list-style-type: none"> • TELBIVUDINE (TYZEKA®) 	<p style="text-align: center;">ADDED TO FORMULARY.</p>	<ul style="list-style-type: none"> • Indication: Treatment of chronic hepatitis B in adult patients with evidence of viral replication and evidence of either persistent transaminase elevations or histologically active disease • Mechanism of Action: Inhibition of HBV polymerase via DNA termination by preferential inhibition of first strand (RNA-dependent) DNA synthesis and second strand (DNA-dependent) DNA synthesis • Adverse effects: Most commonly: muscle related symptoms (CK elevations in 9% in trials), fatigue/malaise, pyrexia, and headache • Precautions: Dosage adjustment recommended for renal dysfunction
<ul style="list-style-type: none"> • GUAIFENESIN CR 600 MG 	<p style="text-align: center;">REMOVED FROM FORMULARY.</p>	<ul style="list-style-type: none"> • All guaifenesin CR products to be discontinued/removed from the market
<ul style="list-style-type: none"> • AUTOMATIC SUBSTITUTIONS 	<ul style="list-style-type: none"> • Statins automatic substitutions: <p style="text-align: center;">Statins Table - automatic substitutor</p> <ul style="list-style-type: none"> • Calcium carbonate 500 mg TO Calcium carbonate 1250 mg (contains 500mg elemental Calcium) 	
<ul style="list-style-type: none"> • AUTOMATIC EXPIRATION 	<ul style="list-style-type: none"> • Pyridium: automatic expiration after 3 days (MD notification will not be sent via Web/VS) 	
<ul style="list-style-type: none"> • VANCOMYCIN TROUGH LEVELS 	<ul style="list-style-type: none"> • Vancomycin goal trough level change FROM 5-10 mcg/ml TO 10-15 mcg/ml for most indications (<i>exceptions: pneumonia and meningeal & parameningeal infections</i>) • Web/VS alert change TO: "A vancomycin trough level between 15-20 mcg/ml is recommended for patients with pneumonia, and meningeal & parameningeal infections" 	
<ul style="list-style-type: none"> • 2007 EMPIRIC TREATMENT RECOMMENDATIONS FOR COMMON ADULT INFECTIONS 	<p style="text-align: center;">2007 Empiric treatment guideline</p>	
<ul style="list-style-type: none"> • BEVACIZUMAB (AVASTIN®) WARNING 	<ul style="list-style-type: none"> • Association of bevacizumab use and formation of tracheoesophageal fistula: <p style="text-align: center;">Avastin & Tracheoesophageal F</p>	

Requests for full monographs or questions regarding this listing may be addressed to the Drug Information Center at (310) 423-3784

Angela Hirai Yang, PharmD
 Hai Tran, PharmD
 Rita Shane, PharmD, FASHP

Pharmacy Program Coordinator
 Clinical Coordinator
 Director, Department of Pharmacy